Biology Reference
In-Depth Information
47. Pommier YDNA. topoisomerase I inhibitors: chemistry, biology,
interfacial inhibition.
Chem Rev
2009;
109
:2894
e
902.
48. Nitiss JL. Targeting DNA topoisomerase II in cancer chemo-
therapy.
Nat Rev Cancer
2009;
9
:338350.
49. Benson III AB. New approaches to assessing and treating early-
stage colon and rectal cancers: cooperative group strategies for
assessing optimal approaches in early-stage disease.
Clin Cancer
Res
2007;
13
:S6913
e
20.
50. Oostendorp LJ, Stalmeier PF, Pasker-de Jong PC, Van der
Graaf WT, Ottevanger PB. Systematic review of benefits and risks
of second-line irinotecan monotherapy for advanced colorectal
cancer.
Anticancer Drugs
2010;
21
:749
e
58.
51. MacCallum C, Gillenwater HH. Second-line treatment of small-
cell lung cancer.
Curr Oncol Rep
2006;
8
:258
e
64.
52. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular
roles of SN-38, a metabolite of the camptothecin derivative CPT-
11, in the antitumor effect of CPT-11.
Cancer Res
1991;
51
:4187
e
91.
53. Sehouli J, Oskay-Ozceli G. (2009) Current role and future aspects
of topotecan in relapsed ovarian cancer.
Curr Med Res Opin
2009;
25
:639
e
51.
54. Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the
second-line treatment of small cell
66. Lieber MR. The mechanism of double-strand DNA break repair
by the nonhomologous DNA end-joining pathway.
Annu Rev
Biochem
2010;
79
:181
e
211.
67. Shibata A, Conrad S, Birraux J, et al. Factors determining DNA
double-strand break repair pathway choice in G2 phase.
EMBO J
2011;
30
(6):1079
e
92.
68. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of
DNA double-strand break repair during the mammalian cell
cycle.
Mol Cell Biol
2003;
23
:5706
e
15.
69. Beucher A, Birraux J, Tchouandong L, et al. ATM and Artemis
promote homologous recombination of radiation-induced DNA
double-strand breaks in G2.
EMBO J
2009;
28
:3413
e
27.
70. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-
strand break repair: from mechanistic understanding to cancer
treatment.
DNA Repair (Amst)
2007;
6
:923
e
35.
71. Sung P, Klein H. Mechanism of homologous recombination:
mediators and helicases take on regulatory functions.
Nat Rev
Mol Cell Biol
2006;
7
:739
e
50.
72. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic
homologous recombination.
Annu Rev Biochem
2008;
77
:229
e
57.
73. Williams RS, Williams JS, Tainer JA. Mre11-Rad50-Nbs1 is
a keystone complex connecting DNA repair machinery, double-
strand break signaling, the chromatin template.
Biochem Cell Biol
2007;
85
:509
e
20.
74. Williams GJ, Lees-Miller SP, Tainer JA. Mre11-Rad50-Nbs1 confor-
mations and the control of sensing, signaling, effector responses
at DNA double-strand breaks.
DNA Repair (Amst)
2010;
9
:1299
e
306.
75. Lamarche BJ, Orazio NI, Weitzman MD. The MRN complex in
double-strand break repair and telomere maintenance.
FEBS Lett
2010;
584
:3682
e
95.
76. Wang H, Perrault AR, Takeda Y, Qin W, Wang H, Iliakis G.
Biochemical evidence for Ku-independent backup pathways of
NHEJ.
Nucleic Acids Res
2003;
31
:5377
e
88.
77. Singh SK, Wu W, Zhang L, Klammer H, Wang M, Iliakis G.
Widespread dependence of backup NHEJ on growth state:
ramifications for the use of DNA-PK inhibitors.
Int J Radiat Oncol
Biol Phys
2011;
79
:540
e
8.
78. Lempiainen H, Halazonetis TD. Emerging common themes in
regulation of PIKKs and PI3Ks.
EMBO J
2009;
28
:3067
e
73.
79. O'Neill T, Dwyer AJ, Ziv Y, et al. Utilization of oriented peptide
libraries to identify substrate motifs selected by ATM.
J Biol Chem
2000;
275
:22719
e
27.
80. Bakkenist CJ, Kastan MB. DNA damage activates ATM through
intermolecular autophosphorylation and dimer dissociation.
Nature
2003;
421
:499
e
506.
81. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a para-
digm for cell signalling and cancer.
Nat Rev Mol Cell Biol
2008;
9
:759
e
69.
82. Kurz EU, Lees-Miller SP. DNA damage-induced activation of
ATM and ATM-dependent signaling pathways.
DNA Repair
(Amst)
2004;
3
:889
e
900.
83. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR
substrate analysis reveals extensive protein networks responsive
to DNA damage.
Science
2007;
316
:1160
e
6.
84. Bennetzen MV, Larsen DH, Bunkenborg J, Bartek J, Lukas J,
Andersen JS. Site-specific phosphorylation dynamics of the
nuclear proteome during the DNA damage response.
Mol Cell
Proteomics
2010;
9
:1314
e
23.
85. Bensimon A, Schmidt A, Ziv Y, et al. ATM-dependent and
-independent dynamics of the nuclear phosphoproteome after
DNA damage.
Sci Signal
2010;
3
:rs3.
86. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA.
ATM and DNA-PK function redundantly to phosphorylate
H2AX after exposure to ionizing radiation.
Cancer Res
2004;
64
:
2390
e
6.
lung cancer.
Oncologist
2009;
14
:986
e
94.
55. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II
in therapy-related acute promyelocytic leukemia.
N Engl J Med
2005;
352
:1529
e
38.
56. Roca J, Ishida R, Berger JM, Oh T, Wang JC. Antitumor bisdiox-
opiperazines inhibit yeast DNA topoisomerase II by trapping the
enzyme in the form of a closed protein clamp.
Proc Natl Acad Sci
USA
91, 1781-1785.
57. Adachi N, Suzuki H, Iiizumi S, Koyama H. Hypersensitivity of
nonhomologous DNA end-joining mutants to VP-16 and ICRF-
193: implications for the repair of topoisomerase II-mediated
DNA damage.
J Biol Chem
2003;
278
:35897
e
902.
58. Jensen LH, Dejligbjerg M, Hansen LT, Grauslund M, Jensen PB,
Sehested M. Characterisation of cytotoxicity and DNA damage
induced by the topoisomerase II-directed bisdioxopiperazine
anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mamma-
lian cells.
BMC Pharmacol
2004;
4
:31.
59. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms
of action and clinical strategies.
Nat Rev Cancer
2003;
3
:330
e
8.
60. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP.
Multiple-treatments meta-analysis of chemotherapy and targeted
therapies
in advanced breast
cancer.
J Natl Cancer
Inst
2008;
100
:1780
e
91.
61. de Campos-Nebel M, Larripa I, Gonzalez-Cid M. Non-homologous
end joining is the responsible pathway for the repair of fludar-
abine-induced DNA double strand breaks in mammalian cells.
Mutat Res
2008;
646
:8
e
16.
62. Liu X, Wang Y, Benaissa S, et al. Homologous recombination as
a resistance mechanism to replication-induced double-strand
breaks caused by the antileukemia agent CNDAC.
Blood
2010;
116
:
1737
e
46.
63. Issaeva N, Thomas HD, Djureinovic T, et al. 6-thioguanine
selectively kills BRCA2-defective tumors and overcomes PARP
inhibitor resistance.
Cancer Res
2010;
70
:6268
e
76.
64. Wachters FM, van Putten JW, Maring JG, Zdzienicka MZ,
Groen HJ, Kampinga HH. Selective targeting of homologous
DNA recombination repair by gemcitabine.
Int J Radiat Oncol Biol
Phys
2003;
57
:553
e
62.
65. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radia-
tion-induced DNA double-strand breaks by non-homologous
end-joining.
Biochem J
2009;
417
:639
e
50.